The third-generation irreversible inhibitor osimertinib is designed to target EGFR T790M, a common mutation in non-small-cell lung cancer (NSCLC), and reduced the resistance that developed after treatment with first- or second-generation inhibitors.61 Preclinically, osimertinib inhibited EGFRvIII-mediated downstream signaling in GSCs, and significantly increased the survival time in mice bearing intracranial EGFRvIII-positive tumors.62 Osimertinib efficiently crosses the blood–brain barrier (BBB), making it an attractive candidate for inhibiting EGFR in GBM. Here, EGFR is linked to non-small cell lung carcinoma.